Analysis of Potential Predictive Markers of Cetuximab Benefit in BMS099, a Phase III Study of Cetuximab and First-Line Taxane/Carboplatin in Advanced Non–Small-Cell Lung Cancer We hypothesized that if ...
Please provide your email address to receive an email when new articles are posted on . “We believe that these results are quite powerful and informative,” Christopher Seder, MD, thoracic surgeon at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results